Obesity Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast to 2031
Summary
Obesity is a complex multifactorial disease characterized by an excess of adipose tissue. It results from an intricate interplay between environmental, genetic, and psychosocial factors, which together arbitrate the balance between food intake and expenditure of energy. Obesity is a primary cause of many life-threatening diseases, including cardiovascular diseases, type 2 diabetes (T2D), chronic kidney disease (CKD), osteoarthritis, metabolic syndrome (MetS), and early mortality.
Growth in the obesity market is expected to be driven by the potential introduction of 13 promising late-stage pipeline products into the market during the forecast period.
This report covers the 7MM (US, France, Germany, Italy, Spain, UK, Japan) and provides an Excel-based forecast model for the obesity market through 2031.
Forecast includes the 7 major markets (7MM)
Forecast covers the period 2021-2031
- Drug sales in the obesity pharmacotherapy market are expected to grow by a significant margin between 2021 and 2031, with an overall compound annual growth rate (CAGR) of 31.3% over the forecast period, reaching $37.1 billion by 2031.
- Growth in the obesity market will be driven by the launch of 13 new pipeline products, including Novo Nordisk’s Wegovy (semaglutide), CagriSema (semaglutide + cagrilintide), and oral semaglutide (NN-9932), Eli Lilly’s tirzepatide, retatrutide, and orforglipron, Versanis Bio’s bimagrumab (BYM338), and Pfizer’s PF-07081532 and danuglipron tromethamine.
- Overview of obesity, including epidemiology, symptoms, diagnosis, and disease management.
- Annualized diabetic neuropathic pain therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2021 to 2031.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the diabetic neuropathic pain therapeutics market.
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for diabetic neuropathic pain treatment. The most promising candidates in Phase III and Phase IIb development are profiled.
- Analysis of the current and future market competition in the global diabetic neuropathic pain therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the 7MM obesity therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM obesity therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- 1 Obesity: Executive Summary
- 1.1 The obesity market will grow significantly during the forecast period, reaching sales of $37.1 billion in 2031
- 1.2 Key players will maintain their competitive position
- 1.3 While the outlook in obesity improves, opportunities remain to improve patient outcomes
- 1.4 Late-stage pipeline therapies are anticipated to drive growth in the obesity market
- 1.5 What do physicians think?
- 2 Introduction
- 2.1 Catalyst
- 2.2 Related reports
- 2.3 Upcoming reports
- 3 Disease Overview
- 3.1 Etiology and pathophysiology
- 3.1.1 Overview
- 3.1.2 Etiology
- 3.1.3 Pathophysiology
- 3.2 Classification or staging systems
- 4 Epidemiology
- 4.1 Disease background
- 4.2 Risk factors and comorbidities
- 4.3 Global and historical trends
- 4.3.1 Total prevalence of overweight
- 4.3.2 Total prevalence of obesity
- 4.3.3 Diagnosed prevalence of overweight
- 4.3.4 Diagnosed prevalence of obesity
- 4.4 7MM forecast methodology
- 4.4.1 Sources
- 4.4.2 Forecast assumptions and methods
- 4.4.3 Total prevalent cases of overweight
- 4.4.4 Total prevalent cases of obesity
- 4.4.5 Total prevalent cases by BMI class
- 4.4.6 Diagnosed prevalent cases of overweight, obesity, and obesity by BMI class
- 4.4.7 Diagnosed incident cases of bariatric surgery
- 4.5 Epidemiological forecast for overweight and obesity (2021-31)
- 4.5.1 Total prevalent cases of overweight
- 4.5.2 Total prevalent cases of obesity
- 4.5.3 Diagnosed prevalent cases of overweight
- 4.5.4 Age-specific diagnosed prevalent cases of overweight
- 4.5.5 Sex-specific diagnosed prevalent cases of overweight
- 4.5.6 Diagnosed prevalent cases of obesity
- 4.5.7 Age-specific diagnosed prevalent cases of obesity
- 4.5.8 Sex-specific diagnosed prevalent cases of obesity
- 4.5.9 Diagnosed prevalent cases of obesity by BMI class
- 4.5.10 Diagnosed incident cases of bariatric surgery
- 4.6 Discussion
- 4.6.1 Epidemiological forecast insight
- 4.6.2 COVID-19 impact
- 4.6.3 Limitations of the analysis
- 4.6.4 Strengths of the analysis
- 5 Disease Management
- 5.1 Diagnosis and treatment overview
- 5.1.1 Diagnosis overview
- 5.1.2 Treatment overview
- 5.2 KOL Insights on Disease Management
- 5.2.1 Guidelines on diagnosis and treatment
- 5.2.2 Treatment approach
- 6 Competitive Assessment
- 6.1 Overview
- 7 Unmet Needs and Opportunity Assessment
- 7.1 Overview
- 7.2 Increased efficacy and weight loss maintenance
- 7.3 Longer-acting therapy
- 7.4 Cost of therapy
- 7.5 Increased public awareness
- 7.6 Availability/accessibility of specialists
- 8 R&D Strategies
- 8.1 Overview
- 8.1.1 Development of novel targets
- 8.1.2 Development of oral agents
- 8.2 Clinical Trials Design
- 8.2.1 Clinical endpoints for obesity
- 8.2.2 Inclusion and exclusion criteria for obesity
- 8.2.3 Trial duration
- 9 Pipeline Assessment
- 9.1 Overview
- 9.2 Promising drugs in clinical development
- 10 Pipeline Valuation Analysis
- 10.1 Overview
- 10.2 Competitive assessment
- 11 Current and Future Players
- 11.1 Overview
- 11.2 Deal-making trends
- 12 Market Outlook
- 12.1 Global markets
- 12.1.1 Forecast
- 12.1.2 Drivers and barriers - global issues
- 12.2 US
- 12.2.1 Forecast
- 12.2.2 Key events
- 12.2.3 Drivers and barriers
- 12.3 5EU
- 12.3.1 Forecast
- 12.3.2 Key events
- 12.3.3 Drivers and barriers
- 12.4 Japan
- 12.4.1 Forecast
- 12.4.2 Key events
- 12.4.3 Drivers and Barriers
- 13 Appendix
- 13.1 Bibliography
- 13.2 Abbreviations
- 13.3 Methodology
- 13.3.1 Forecasting methodology
- 13.4 Primary research - key opinion leaders interviewed for this report
- 13.4.1 Key opinion leaders
- 13.5 Primary research - prescriber survey
- 13.6 About the authors
- 13.6.1 Analyst
- 13.6.2 Therapy Area Director
- 13.6.3 Epidemiologist
- 13.6.4 Reviewers
- 13.6.5 Vice President of Disease Analysis and Intelligence
- 13.6.6 Global Head and EVP of Healthcare Operations and Strategy
- Contact Us
- List of Tables
- Table 1: Obesity: key metrics in the 7MM
- Table 2: Classifications of obesity as outlined by the WHO
- Table 3: Classification systems for obesity based on BMI cut-off points
- Table 4: Risk factors and comorbidities for obesity
- Table 5: Treatment guidelines for obesity
- Table 6: Top 10 deals by value, 2017-22
- Table 7: Obesity market - global drivers and barriers, 2021-31
- Table 8: Key events impacting sales for obesity in the US, 2021-31
- Table 9: Obesity market - drivers and barriers in the US, 2021-31
- Table 10: Key events impacting sales for obesity in the 5EU, 2021-2031
- Table 11: Obesity market - drivers and barriers in the 5EU, 2021-31
- Table 12: Key events impacting sales for Obesity in Japan, 2021-31
- Table 13: Obesity market - drivers and barriers in Japan, 2021-2031
- Table 14: High-prescribing physicians (non-KOLs) surveyed, by country
- List of Figures
- Figure 1: Global sales forecast by country for obesity in 2021 and 2031
- Figure 2: Analysis of the company portfolio gap in obesity during the forecast period
- Figure 3: Competitive assessment of the late-stage pipeline agents that GlobalData expects to be licensed for the treatment of obesity during the forecast period
- Figure 4: Factors involved in the etiology of obesity
- Figure 5: Pathophysiological manifestation of obesity
- Figure 6: 7MM, total prevalence of overweight, men and women, ages ≥5 years, 2011-31 (%)
- Figure 7: 7MM, total prevalence of obesity, men and women, ages ≥5 years, 2011-31 (%)
- Figure 8: 7MM, diagnosed prevalence of overweight, men and women, ages ≥5 years, 2011-31 (%)
- Figure 9: 7MM, diagnosed prevalence of obesity, men and women, ages ≥5 years, 2011-31 (%)
- Figure 10: 7MM, sources used to forecast the total and diagnosed prevalent cases of overweight and obesity
- Figure 11: 7MM, sources used and not used to forecast the total and diagnosed prevalent cases of Class I, Class II, and Class III obesity
- Figure 12: 7MM, sources used and not used to forecast diagnosed incidence of bariatric surgery
- Figure 13: 7MM, total prevalent cases of overweight, men and women, ages ≥5 years, 2021 (N)
- Figure 14: 7MM, total prevalent cases of obesity, men and women, ages ≥5 years, 2021 (N)
- Figure 15: 7MM, diagnosed prevalent cases of overweight, men and women, ages ≥5 years, 2021 (N)
- Figure 16: 7MM, diagnosed prevalent cases of overweight by age, men and women, 2021 (N)
- Figure 17: 7MM, diagnosed prevalent cases of overweight by sex, ages ≥5 years, 2021 (N)
- Figure 18: 7MM, diagnosed prevalent cases of obesity, men and women, ages ≥5 years, 2021 (N)
- Figure 19: 7MM, diagnosed prevalent cases of obesity by age, men and women, 2021 (N)
- Figure 20: 7MM, diagnosed prevalent cases of obesity by sex, ages ≥5 years, 2021 (N)
- Figure 21: 7MM, diagnosed prevalent cases of obesity by BMI class, men and women, ages ≥5 years, 2021 (N)
- Figure 22: 7MM, diagnosed incident cases of bariatric surgery, men and women, all ages, 2021 (N)
- Figure 23: BMI chart as a diagnostic technique for obesity
- Figure 24: Treatment algorithm for obesity
- Figure 25: Unmet needs and opportunities in obesity
- Figure 26: Overview of the development pipeline in obesity
- Figure 27: Key late-stage trials for the promising pipeline agents that GlobalData expects be licensed for obesity in the 7MM during the forecast period
- Figure 28: Competitive assessment of the recently approved agents and late-stage pipeline agents that GlobalData expects to be licensed for the treatment of obesity during the forecast period
- Figure 29: Competitive assessment of the marketed and pipeline drugs benchmarked against the standard of care, Wegovy
- Figure 30: Analysis of the company portfolio gap in obesity during the forecast period
- Figure 31: Global (7MM) sales forecast by country for obesity in 2021 and 2031
- Figure 32: Global (7MM) sales forecast by drug for obesity in 2021 and 2031
- Figure 33: Sales forecast by drug for obesity in the US in 2021 and 2031
- Figure 34: Sales forecast by drug for obesity in the 5EU in 2021 and 2031
- Figure 35: Sales forecast by drug for obesity in Japan in 2021 and 2031
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook